查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363247

肉瘤治疗药物市场规模、份额、趋势分析报告：依治疗类型、配销通路、地区、细分趋势，2023-2030

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 93 Pages | 商品交期: 2-10个工作天内

价格

肉瘤治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球肉瘤治疗市场规模将达到25.345亿美元，2023年至2030年年复合成长率为8.9%。

市场成长主要是由新产品发布、新型疗法的采用增加以及目标人口等要素所推动的。

肉瘤占成人所有癌症的比例不到 1.0%。肉瘤是一个异质性群体，由 50 多种不同的组织学类型组成，但两个主要亚型是软组织肉瘤 (STS) 和骨癌。美国每年约有 12,000 人被诊断出患有 STS，欧洲每年约有 28,000 人被诊断出患有 STS。

40多年来，局部肉瘤的主要治疗方法一直是手术切除，然后进行新辅助或辅助放射线治疗和化疗。然而，即使完全手术切除，大约 50.0% 的恶性肉瘤患者也会发生转移。标靶治疗的引入彻底改变了肉瘤的治疗模式。在整个预测期内，标靶治疗和管道突破将继续在市场成长中发挥关键作用。

肉瘤药物市场报告亮点

  • 到2022年，EU5仍将是第二大市场，份额将超过20%。此细分市场的成长归因于 STS罹患率的上升、标靶治疗的广泛普及以及研发活动的活性化。
  • 礼来公司的 Lartuvo 已取代标准阿霉素疗法作为 STS 的一线治疗方法，预计在预测期内将保持其市场主导地位。
  • 该市场存在强烈的未满足需求，为开发创新的一流治疗方法创造了重要机会。在肉瘤管道中的 45 种药物中，7 种处于 III 期，22 种处于 II 期，2 种处于 I/II 期试验，其余处于 I 期和临床前试验。
  • 目前正在 I/II 期临床试验中评估免疫肿瘤药物在肉瘤中的潜在作用。
  • 阶段阶段的新标靶药物包括诺华的Afinitor（mTOR抑制剂）、Tesaro的Zejula（PARP抑制剂）、安进的Imlygic（基因疗法）、辉瑞的Crizotinib（ALK和MET酪胺酸激酶抑制剂）等。

目录

第1章调查方法与范围

第2章执行摘要

第3章肉瘤药物市场：变数、趋势、范围

  • 市场体系预测
  • 普及和成长预测图
  • 产业价值链分析
  • 市场动态
  • 肉瘤药物市场分析工具

第4章肉瘤治疗药物市场：治疗类型估计和趋势分析

  • 肉瘤药物市场：要点
  • 肉瘤药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 化疗
  • 标靶治疗

第5章肉瘤治疗药物市场：配销通路估算与趋势分析

  • 肉瘤药物市场：要点
  • 肉瘤药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 医院药房
  • 零售药房
  • 网路药房

第6章肉瘤治疗药物市场：区域估计和趋势分析

  • 区域预测
  • 肉瘤药物市场：按地区：主要市场亮点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Pfizer Inc.
    • Novartis International AG
    • Eli Lilly and Company
    • Bayer AG
    • Eisai Co.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Daiichi Sankyo Company, Limited
Product Code: GVR-2-68038-528-1

Sarcoma Drugs Market Growth & Trends:

The global sarcoma drugs market size is expected to be valued at USD 2534.5 million by 2030, as per a new report by Grand View Research, Inc.., progressing at a CAGR of 8.9% from 2023 to 2030. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Sarcoma Drugs Market Report Highlights:

  • EU5 will remain the second largest market with more than 20% share by 2022. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
  • Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
  • Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
  • The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
  • Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment type
    • 1.1.2. Distribution channel
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. Distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Sarcoma Drugs Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
  • 3.5. Sarcoma Drugs Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape

Chapter 4. Sarcoma Drugs Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Sarcoma Drugs Market: Key Takeaways
  • 4.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Targeted therapy
    • 4.4.1. Targeted therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sarcoma Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Sarcoma Drugs Market: Key Takeaways
  • 5.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospital pharmacy
    • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Retail pharmacy
    • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Online pharmacy
    • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sarcoma Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Sarcoma Drugs Market: by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Pfizer Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Novartis International AG
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Eli Lilly and Company
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Bayer AG
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Eisai Co.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Johnson & Johnson
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co. Inc
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Daiichi Sankyo Company, Limited
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 3 North America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 4 North America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 6 U.S. sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 8 Canada sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Europe sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 10 Europe sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Europe sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 12 Germany sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 13 Germany sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 UK sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 15 UK sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 France sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 17 France sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 Italy sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 19 Italy sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Spain sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 21 Spain sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Sweden sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 23 Sweden sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Norway sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 25 Norway sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Denmark sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 27 Denmark sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 31 China sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 32 China sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 China sarcoma drugs market: by application, 2018 - 2030 (USD Million)
  • Table 34 Japan sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 35 Japan sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Japan sarcoma drugs market: by application, 2018 - 2030 (USD Million)
  • Table 37 India sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 38 India sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Australia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 40 Australia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Thailand sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 42 Thailand sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 South Korea sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 44 South Korea sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Latin America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 46 Latin America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Latin America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 48 Brazil sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 49 Brazil sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Mexico sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 51 Mexico sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Argentina sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 53 Argentina sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 55 Middle East and Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East and Africa sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 57 South Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 58 South Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 UAE sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 62 UAE sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 Kuwait sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 64 Kuwait sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Sarcoma drugs market: Market outlook
  • Fig. 9 Sarcoma drugs market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Sarcoma drugs market: driver impact
  • Fig. 15 Sarcoma drugs market: restraint impact
  • Fig. 16 Sarcoma drugs market: Strategic Initiatives analysis
  • Fig. 17 Sarcoma drugs market: Treatment type movement analysis
  • Fig. 18 Sarcoma drugs market: Treatment type outlook and key takeaways
  • Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030
  • Fig. 20 Targeted therapy & others market estimates and forecasts, 2018 - 2030
  • Fig. 21 Sarcoma drugs market: Distribution channel movement analysis
  • Fig. 22 Sarcoma drugs market: Distribution channel outlook and key takeaways
  • Fig. 23 Hospital pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 24 Retail pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 25 Online pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 26 Global Sarcoma drugs market: Regional movement analysis
  • Fig. 27 Global Sarcoma drugs market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 34 France market estimates and forecasts, 2018 - 2030
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 42 China market estimates and forecasts, 2018 - 2030
  • Fig. 43 India market estimates and forecasts, 2018 - 2030
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030